Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial

Journal:

The Lancet

Published:

2025-06-24

DOI:

10.1016/s0140-6736(25)00778-0

Affiliations:

5

Authors:

18

Go to article

Institutions	Authors	Share
Stanford University, United States of America (USA)	10.500000 10.500000	0.58
Abeona Therapeutics, United States of America (USA)	4.000000	0.22
University of Massachusetts Chan Medical School (UMass Chan Medical School), United States of America (USA)	2.000000	0.11
University of Colorado Anschutz Medical Campus (CU Anschutz), United States of America (USA)	1.000000	0.06
VA Palo Alto Healthcare System (VAPAHCS), United States of America (USA)	0.500000	0.03

Interested in Clinical Sciences?